Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

In a report released today, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $175.00. The company’s shares closed yesterday at $152.67.

According to TipRanks, Singh Chadha is a 2-star analyst with an average return of 0.6% and a 44.27% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Zynex, and Axonics Modulation Technologies.

In addition to RBC Capital, Johnson & Johnson also received a Buy from Leerink Partners’s David Risinger in a report issued on May 6. However, on May 9, Wells Fargo maintained a Hold rating on Johnson & Johnson (NYSE: JNJ).

Based on Johnson & Johnson’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $21.38 billion and a net profit of $3.26 billion. In comparison, last year the company earned a revenue of $24.75 billion and had a GAAP net loss of $68 million

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Johnson & Johnson (JNJ) Company Description:

Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.